Home
/
BIOCRYST PHARMACEUTICALS INC
/
Financials
/
Quarterly
BIOCRYST PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BIOCRYST PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$8.76M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$3.10M
Aug 8, 2017
Q1
2017
Mar 31, 2017
$9.44M
May 8, 2017
Q3
2017
Sep 30, 2016
$7.76M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$4.79M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$4.82M
May 8, 2017
Q3
2016
Sep 30, 2015
$10.99M
Nov 8, 2016
Q2
2016
Jun 30, 2015
$25.84M
Aug 8, 2016
Q1
2016
Mar 31, 2015
$6.83M
May 9, 2016
Q3
2015
Sep 30, 2014
$3.24M
Nov 6, 2015
Q2
2015
Jun 30, 2014
$1.47M
Aug 7, 2015
Q1
2015
Mar 31, 2014
$3.46M
May 8, 2015
Q3
2014
Sep 30, 2013
$2.39M
Nov 7, 2014
Q2
2014
Jun 30, 2013
$821.0K
Aug 8, 2014
Q1
2014
Mar 31, 2013
$3.55M
May 9, 2014
Q3
2013
Sep 30, 2012
$5.76M
Nov 8, 2013
Q2
2013
Jun 30, 2012
$4.21M
Aug 8, 2013
Q1
2013
Mar 31, 2012
$12.22M
May 9, 2013
Q3
2012
Sep 30, 2011
$5.25M
Nov 8, 2012
Q2
2012
Jun 30, 2011
$3.74M
Aug 8, 2012
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$8.76M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$3.10M
Aug 8, 2017
Q1
2017
Mar 31, 2017
$9.44M
May 8, 2017
Q3
2017
Sep 30, 2016
$7.76M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$4.79M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$4.82M
May 8, 2017
Q3
2016
Sep 30, 2015
$10.99M
Nov 8, 2016
Q2
2016
Jun 30, 2015
$25.84M
Aug 8, 2016
Q1
2016
Mar 31, 2015
$6.83M
May 9, 2016
Q3
2015
Sep 30, 2014
$3.24M
Nov 6, 2015
Q2
2015
Jun 30, 2014
$1.47M
Aug 7, 2015
Q1
2015
Mar 31, 2014
$3.46M
May 8, 2015
Q3
2014
Sep 30, 2013
$2.39M
Nov 7, 2014
Q2
2014
Jun 30, 2013
$821.0K
Aug 8, 2014
Q1
2014
Mar 31, 2013
$3.55M
May 9, 2014
Q3
2013
Sep 30, 2012
$5.76M
Nov 8, 2013
Q2
2013
Jun 30, 2012
$4.21M
Aug 8, 2013
Q1
2013
Mar 31, 2012
$12.22M
May 9, 2013
Q3
2012
Sep 30, 2011
$5.25M
Nov 8, 2012
Q2
2012
Jun 30, 2011
$3.74M
Aug 8, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$12.90M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$5.09M
Aug 5, 2025
Q3
2025
Jun 30, 2025
$5.09M
Nov 4, 2025
Q1
2025
Mar 31, 2025
$32.0K
May 6, 2025
Q3
2025
Mar 31, 2025
$32.0K
Nov 4, 2025
Q2
2025
Mar 31, 2025
$32.0K
Aug 5, 2025
Q3
2025
Sep 30, 2024
($14.03M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($12.67M)
Aug 5, 2025
Q3
2025
Jun 30, 2024
($12.67M)
Nov 4, 2025
Q3
2025
Mar 31, 2024
($35.38M)
Nov 4, 2025
Q2
2025
Mar 31, 2024
($35.38M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($35.38M)
May 6, 2025
Q3
2024
Sep 30, 2023
($36.15M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($75.33M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($75.33M)
Nov 5, 2024
Q3
2024
Mar 31, 2023
($53.33M)
Nov 5, 2024
Q1
2024
Mar 31, 2023
($53.33M)
May 7, 2024
Q2
2024
Mar 31, 2023
($53.33M)
Aug 6, 2024
Q3
2023
Sep 30, 2022
($42.52M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($58.86M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$29.59M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$29.79M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$21.23M
May 6, 2025
Q3
2025
Sep 30, 2024
$7.69M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$8.76M
Aug 5, 2025
Q1
2025
Mar 31, 2024
($14.49M)
May 6, 2025
Q3
2024
Sep 30, 2023
($11.92M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($20.70M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($28.42M)
May 7, 2024
Q3
2023
Sep 30, 2022
($17.45M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($34.72M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($49.96M)
May 8, 2023
Q3
2022
Sep 30, 2021
($44.58M)
Nov 4, 2022
Q2
2022
Jun 30, 2021
($29.58M)
Aug 5, 2022
Q1
2022
Mar 31, 2021
($51.38M)
May 9, 2022
Q3
2021
Sep 30, 2020
($42.86M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($38.51M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($40.98M)
May 7, 2021
Q3
2020
Sep 30, 2019
($35.10M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($34.92M)
Aug 7, 2020